OncoMatch/Clinical Trials/NCT06943820
AK129 Combination Therapy for Advanced Solid Tumors
Is NCT06943820 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments for non-small cell lung cancer stage iiib/iv.
Treatment: AK129(dose 1) · Pemetrexed · Paclitaxel · Carboplatin · AK129(dose 2) · Docetaxel · Cis-platinum · 5-FU (5-fluorouracil) · Cetuximab · Paclitaxel · Docetaxel · Chemotherapy · AK129(RP2D) · Penpulimab — This is an open, multicenter phase Ib/II clinical study. The goal of this study is to confirm the Phase II recommended dose (RP2D) of AK129 combinations for advanced solid tumors and evaluate the safety and efficacy of AK129 combinations for non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), colorectal adenocarcinoma (CRC), and other advanced solid tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Head and Neck Squamous Cell Carcinoma
Colorectal Cancer
Tumor Agnostic
Biomarker criteria
Excluded: EGFR sensitizing mutation
EGFR-sensitive mutations
Excluded: EGFR exon 20 insertion mutation
EGFR exon 20 insertion mutation
Excluded: ALK fusion
ALK fusion positivite
Excluded: ROS1 rearrangement
known ROS1 rearrangement
Excluded: MET exon 14 skipping mutation
MET exon 14 skipping mutation
Excluded: BRAF V600E mutation
BRAF V600E mutation
Excluded: NTRK1 fusion
NTRK gene fusion positivite
Excluded: NTRK2 fusion
NTRK gene fusion positivite
Excluded: NTRK3 fusion
NTRK gene fusion positivite
Excluded: RET fusion
RET gene fusion positivite
Disease stage
Required: Stage IIIB, IIIC, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy — locally advanced or metastatic NSCLC
must have received a platinum-based combination therapy and a PD-(L)1 monoclonal antibody for the treatment of locally advanced or metastatic disease and progressed during or after receiving prior therapy
Must have received: anti-PD-1 therapy — locally advanced or metastatic NSCLC
must have received a platinum-based combination therapy and a PD-(L)1 monoclonal antibody for the treatment of locally advanced or metastatic disease and progressed during or after receiving prior therapy
Must have received: platinum-based chemotherapy — recurrent or metastatic HNSCC
must have received a platinum-based combination therapy and a PD-(L)1 monoclonal antibody for the treatment of recurrent or metastatic disease and progressed during or after receiving prior therapy
Must have received: anti-PD-1 therapy — recurrent or metastatic HNSCC
must have received a platinum-based combination therapy and a PD-(L)1 monoclonal antibody for the treatment of recurrent or metastatic disease and progressed during or after receiving prior therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify